Complications, Diagnosis, Management, and Prevention of CMV Infections: Current and Future

被引：64

作者：

Boeckh, Michael ^{[1
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2011年

基金：

美国国家卫生研究院;

关键词：

CELL TRANSPLANT RECIPIENTS; CYTOMEGALOVIRUS-INFECTION; DOUBLE-BLIND; MARIBAVIR PROPHYLAXIS; PP65; ANTIGENEMIA; DISEASE; GANCICLOVIR; IMPACT; DONOR; RISK;

D O I：

10.1182/asheducation-2011.1.305

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

Although major progress has been made in the prevention of CMV disease after hematopoietic cell transplantation (HCT), specific problems remain and available antiviral agents are associated with major toxicities. This article reviews current aspects of CMV diagnosis, prevention, and treatment in HCT recipients and defines areas of unmet medical need.

引用

页码：305 / 309

页数：5

共 40 条

[1] Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients [J].

Avery, R. K. ;

Marty, F. M. ;

Strasfeld, L. ;

Lee, I. ;

Arrieta, A. ;

Chou, S. ;

Tatarowicz, W. ;

Villano, S. .

TRANSPLANT INFECTIOUS DISEASE, 2010, 12 (06) :489-496

[2] The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy [J].

Boeckh, M ;

Nichols, WG .

BLOOD, 2004, 103 (06) :2003-2008

[3] Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies [J].

Boeckh, M ;

Nichols, WG ;

Papanicolaou, G ;

Rubin, R ;

Wingard, JR ;

Zaia, Y .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (09) :543-558

[4] Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity [J].

Boeckh, M ;

Leisenring, W ;

Riddell, SR ;

Bowden, RA ;

Huang, ML ;

Myerson, D ;

Stevens-Ayers, T ;

Flowers, MED ;

Cunningham, T ;

Corey, L .

BLOOD, 2003, 101 (02) :407-414

[5] Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study [J].

Boeckh, M ;

Gooley, TA ;

Myerson, D ;

Cunningham, T ;

Schoch, G ;

Bowden, RA .

BLOOD, 1996, 88 (10) :4063-4071

[6] Cytomegalovirus: pathogen, paradigm, and puzzle [J].

Boeckh, Michael ;

Geballe, Adam P. .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (05) :1673-1680

[7] How I treat cytomegalovirus in hematopoietic cell transplant recipients [J].

Boeckh, Michael ;

Ljungman, Per .

BLOOD, 2009, 113 (23) :5711-5719

[8] Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir [J].

Chou, Sunwen .

REVIEWS IN MEDICAL VIROLOGY, 2008, 18 (04) :233-246

[9] Immunobiology of Human Cytomegalovirus: from Bench to Bedside [J].

Crough, Tania ;

Khanna, Rajiv .

CLINICAL MICROBIOLOGY REVIEWS, 2009, 22 (01) :76-+

[10] Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation [J].

Einsele, H ;

Reusser, P ;

Bornhäuser, M ;

Kalhs, P ;

Ehninger, G ;

Hebart, H ;

Chalandon, Y ;

Kröger, N ;

Hertenstein, B ;

Rohde, F .

BLOOD, 2006, 107 (07) :3002-3008

← 1 2 3 4 →